CoChat

Neuroprotective Properties and Therapeutic Potential of Bone Marrow–Derived Microglia in Alzheimer’s Disease

Open access
Li, Chang, Chen, Yu-Hua, Zhang, Ke · 2020 · American Journal of Alzheimer's Disease & Other Dementias®

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common form of dementia, which is characterized by a progressive cognitive decline and senile plaques formed by amyloid β (Aβ). Microglia are the immune cells of the central nervous system (CNS). Studies have proposed 2 types of microglia, namely, the resident microglia and bone marrow–derived microglia (BMDM). Recent studies suggested that BMDM, not the resident microglia, can phagocytose Aβ, which has a great therapeutic potential in AD. Bone marrow–derived microglia can populate the CNS in an efficient manner and their functions can be regulated by some genes. Thus, methods that increase their recruitment and phagocytosis could be used as a new tool that clears Aβ and ameliorates cognitive impairment. Herein, we review the neuroprotective functions of BMDM and their therapeutic potential in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1533317520927169

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. A multistep process of bone marrow–derived microglia (BMDM) recruitment into brain in Alzheimer’s disease (AD). With stimulation of amyloid β (Aβ), the recruitment of BMDM is enhanced. CC-chemokine ligand 2 (CCL2) is produced by brain cells. CC-chemokine receptor 2 (CCR2)/CCL2 is necessary for cells engraftment from bone marrow into blood. Chemokine (C-X-Cmotif) ligand 1 (CXCL1), after binding with CXC chemokine receptor 2 (CXCR2) in human brain microvascular endothelial cells, derives transendothelial migration of bone morrow–derived cells and stromal-derived factor 1 (SDF-1)/ CXC chemokine receptor 4 (CXCR4) controls the trafficking of monocytes into the brain parenchyma.
Figure 1. A multistep process of bone marrow–derived microglia (BMDM) recruitment into brain in Alzheimer’s disease (AD). With stimulation of amyloid β (Aβ), the recruitment of BMDM is enhanced. CC-chemokine ligand 2 (CCL2) is produced by brain cells. CC-chemokine receptor 2 (CCR2)/CCL2 is necessary for cells engraftment from bone marrow into blood. Chemokine (C-X-Cmotif) ligand 1 (CXCL1), after binding with CXC chemokine receptor 2 (CXCR2) in human brain microvascular endothelial cells, derives transendothelial migration of bone morrow–derived cells and stromal-derived factor 1 (SDF-1)/ CXC chemokine receptor 4 (CXCR4) controls the trafficking of monocytes into the brain parenchyma.CC BY · PubMed Central
Figure 2. Potential treatment strategy of bone marrow–derived microglia (BMDM) recruitment into the brain. The treatment acts on different stages in the pathogenesis of Alzheimer’s disease (AD). This treatment clears amyloid β (Aβ) ultimately involved stimulating recruitment of BMDM, promoting BMDM clearing Aβ.
Figure 2. Potential treatment strategy of bone marrow–derived microglia (BMDM) recruitment into the brain. The treatment acts on different stages in the pathogenesis of Alzheimer’s disease (AD). This treatment clears amyloid β (Aβ) ultimately involved stimulating recruitment of BMDM, promoting BMDM clearing Aβ.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 2

  1. Wyss-Coray T, 2006, Nat Med, 12, 1005
  2. Ende N, 2001, J Med, 32, 241

Cited by

See all 17

Metadata

Authors
Li, C., Chen, Y.-H., & Zhang, K.
Affiliations
  • Sheng Jing Hospital (CN)
  • Department of Developmental Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China
  • China Medical University (CN)
Corresponding author
Zhang, Ke
Venue
American Journal of Alzheimer's Disease & Other Dementias®
Published
2020-01-01
Volume
35
Pages
1533317520927169-1533317520927169
ISSN
  • 0888-4897 (ISSN-L)
  • 1533-3175
  • 1938-2731
OpenAlex
W3035574310
Cited by
17
References
59
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 1 · 2020: 1
FWCI
0.30
Type
journal article
Language
en
Open access
Locations
  • American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (31571057)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, microglia, amyloid-beta, phagocytosis, neuroprotection, cognitive impairment, amyloid plaques, microglial recruitment, therapeutic potential
MeSH terms
Neuroprotection, Alzheimer Disease, Bone Marrow Cells, Humans, Phagocytosis, Amyloid beta-Peptides, Microglia, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroprotective Properties and Therapeutic Potential of Bone Marrow–Derived Microglia in Alzheimer’s Disease. https://app.cochat.ai/papers/10.1177/1533317520927169
The paper
Li, C., Chen, Y.-H., & Zhang, K. (2020). Neuroprotective Properties and Therapeutic Potential of Bone Marrow–Derived Microglia in Alzheimer’s Disease. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317520927169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.